Reliability of the Matson Evaluation of Drug Side Effects scale (MEDS)

Matson, Johnny L.; Mayville, Erik A.; Bielecki, JoAnne; Barnes, W.Harvin; Bamburg, Jay W.; Baglio, Christopher S.

doi:10.1016/s0891-4222(98)00021-3

Cited by 83 publications

(24 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Medication side effects were then classified into the following categories: metabolic (e.g., weight gain, increased appetite, increased blood pressure, increased blood sugar), cardiac (e.g., increased heart rate), movement (e.g., muscle stiffness, tics, involuntary movements), fatigue/sleep (e.g., lethargy, somnolence, sedation, nightmares), general neurological change (e.g., headaches, dizziness, disorientation, slowed down, subdued), behaviour change (e.g., mania, fixed thoughts, aggression, anxiety, irritable, depression), serious neurological events (e.g., seizure), endocrine (e.g., lactation, breast growth), dermatological (e.g., acne), gastrointestinal (e.g., constipation, loose bowels, nausea), hematological (e.g., nose bleed, low iron), temperature dysregulation (e.g., heat sensitivity, fever), weight loss, thirst, sexual (e.g., sexual dysfunction), and genitourinary (e.g., urinary retention). Classifications were based on literature on medication side effects (AHFS, 2014;Matson et al, 1998), and side effects were independently verified and coded by two authors (VV, AS).…”

Section: Medication and Side Effectsmentioning

confidence: 99%

Psychotropic Medication Use Among Adolescents and Young Adults with an Autism Spectrum Disorder: Parent Views About Medication Use and Healthcare Services

Lake

Vogan²,

Sawyer³

et al. 2015

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objectives: Psychotropic medications are frequently used to treat mental health and behavioral issues in adolescents and adults with an autism spectrum disorder (ASD).Although parents of individuals with ASD frequently take on medication management for their child, there is limited literature on parent perspectives of their child's medication use or their views about the health care services they receive, particularly in adulthood.The current study examined and compared parents of adolescents and of young adults with ASD on their child's psychotropic medication use and their views about health care services. Methods: One hundred parents of adolescents and young adults with ASD (ages 12-30 years) completed an online survey about their experience with their child's health care services and medication use. Results: Parents of young adults were less likely to use non-pharmacological services before using a psychotropic medication compared to parents of adolescents. Parents of young adults were also less likely to believe their prescribing health care provider had adequate expertise in ASD and were less satisfied with how their prescriber monitored their child's medication use. Conclusion: Findings highlight the need to build capacity among health care providers supporting individuals with ASD as they transition into adulthood. There is also a need for improved medication monitoring and increased awareness of the different mental health challenges individuals with ASD encounter as they age. We know even less about parent perspectives as individuals with ASD enter adulthood, when the needs of patients and families may change (Graetz 2010). This transition can be particularly challenging for individuals with ASD, not only in terms of physiological changes, but also because of possible changes to residence, education, and employment. Additionally, young adults may encounter significant changes in service eligibility or accessibility, and some adults may no longer be eligible or have access to funded non-pharmacological services or supports. For example, adolescents access services through children's services and the school system, whereas young adults receive services within the adult system. Further, young adults must move from the pediatric to the adult health care system, where access to health care professionals and trainees who have the capacity and expertise to care for individuals with ASD is sparse (Bruder et al. 2012;Cheak-Zamora et al. 2013;Marrus et al. 2014). Lastly, medication efficacy, tolerability, and the reason(s) for prescribing medication or the individual's psychiatric presentation, may also differ between the two groups. For these reasons, there is a clear need to better understand the unique experience of medication use among transitioning youth with ASD, and how these experiences differ from younger adolescents.In the only study to examine parent perspectives on psychotropic medication use among adolescents and adults with ASD, we identified a number of key concerns related to medication u...

show abstract

Section: Medication and Side Effectsmentioning

confidence: 99%

Psychotropic Medication Use Among Adolescents and Young Adults with an Autism Spectrum Disorder: Parent Views About Medication Use and Healthcare Services

Lake

Vogan²,

Sawyer³

et al. 2015

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…We also monitored subjective reports of adverse events and participants completed the Side-Effects Checklist at each visit. 28 …”

Section: Assessmentsmentioning

confidence: 99%

A Pilot Study of Rhodiola rosea (Rhodax^®) for Generalized Anxiety Disorder (GAD)

Bystritsky

Kerwin²,

Feusner³

2008

The Journal of Alternative and Complementary Medicine

View full text Add to dashboard Cite

show abstract

“…Although the newer, atypical anti-psychotics have been promoted as having less propensity to cause EPSEs than older drugs, there is evidence that those with ID who take atypical antipsychotic drugs remain at increased risk of developing abnormal movement disorders (Fodstad et al 2010). The Matson Evaluation of Drug Side-Effects (MEDS) has been developed as a comprehensive informant-based measure that can be used to assess sideeffects of psychotropic medication in people with ID (Matson et al 1998). …”

Section: Pharmacological Treatmentmentioning

confidence: 99%

Schizophrenia spectrum disorders

Sheehan¹,

Fodor-Wynne²,

Hassiotis³

2015

Psychiatric and Behavioral Disorders in Intellectual and Developmental Disabilities

View full text Add to dashboard Cite

Reliability of the Matson Evaluation of Drug Side Effects scale (MEDS)

Cited by 83 publications

References 7 publications

Psychotropic Medication Use Among Adolescents and Young Adults with an Autism Spectrum Disorder: Parent Views About Medication Use and Healthcare Services

Psychotropic Medication Use Among Adolescents and Young Adults with an Autism Spectrum Disorder: Parent Views About Medication Use and Healthcare Services

A Pilot Study of Rhodiola rosea (Rhodax^®) for Generalized Anxiety Disorder (GAD)

Schizophrenia spectrum disorders

Contact Info

Product

Resources

About

Reliability of the Matson Evaluation of Drug Side Effects scale (MEDS)

Cited by 83 publications

References 7 publications

Psychotropic Medication Use Among Adolescents and Young Adults with an Autism Spectrum Disorder: Parent Views About Medication Use and Healthcare Services

Psychotropic Medication Use Among Adolescents and Young Adults with an Autism Spectrum Disorder: Parent Views About Medication Use and Healthcare Services

A Pilot Study of Rhodiola rosea (Rhodax®) for Generalized Anxiety Disorder (GAD)

Schizophrenia spectrum disorders

Contact Info

Product

Resources

About

A Pilot Study of Rhodiola rosea (Rhodax^®) for Generalized Anxiety Disorder (GAD)